Worldwide use of HPV self-sampling for cervical cancer screening

An increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human Papillomavirus (HPV) screening. Self-sampling effectively reaches underscreened women and can be a powerful strategy in low- and high-resource settings for all target age...

Descripción completa

Detalles Bibliográficos
Autores: Serrano, Beatriz, Ibáñez, Raquel, Robles, Claudia, Peremiquel Trillas, Paula, Sanjosé Llongueras, Silvia de, Bruni, Laia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/192488
Acceso en línea:https://hdl.handle.net/2445/192488
Access Level:acceso abierto
Palabra clave:Papil·lomavirus
Cribratge
Càncer de coll uterí
Papillomaviruses
Medical screening
Cervix cancer
id ES_816b8a5c1eb16bee72ebfbcece36d882
oai_identifier_str oai:diposit.ub.edu:2445/192488
network_acronym_str ES
network_name_str España
repository_id_str
spelling Worldwide use of HPV self-sampling for cervical cancer screeningSerrano, BeatrizIbáñez, RaquelRobles, ClaudiaPeremiquel Trillas, PaulaSanjosé Llongueras, Silvia deBruni, LaiaPapil·lomavirusCribratgeCàncer de coll uteríPapillomavirusesMedical screeningCervix cancerAn increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human Papillomavirus (HPV) screening. Self-sampling effectively reaches underscreened women and can be a powerful strategy in low- and high-resource settings for all target ages. This work aims to summarize the current use of HPV self-sampling worldwide. It is part of a larger project that describes cervical cancer screening programmes and produces standardized coverage estimates worldwide. A systematic review of the literature and official documents supplemented with a formal World Health Organisation country consultation was conducted. Findings show that the global use of HPV self-sampling is still limited. Only 17 (12%) of countries with identified screening programs recommend its use, nine as the primary collection method, and eight to reach underscreened populations. We identified 10 pilots evaluating the switch to self-sampling in well-established screening programs. The global use of self-sampling is likely to increase in the coming years. COVID-19's pandemic has prompted efforts to accelerate HPV self-sampling introduction globally, and it is now considered a key element in scaling up screening coverage. The information generated by the early experiences can be beneficial for decision-making in both new and existing programs.Elsevier BV2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/192488Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.ypmed.2021.106900Preventive Medicine, 2022, vol. 154, p. 106900https://doi.org/10.1016/j.ypmed.2021.106900cc by (c) Serrano, Beatriz et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1924882026-05-27T06:46:51Z
dc.title.none.fl_str_mv Worldwide use of HPV self-sampling for cervical cancer screening
title Worldwide use of HPV self-sampling for cervical cancer screening
spellingShingle Worldwide use of HPV self-sampling for cervical cancer screening
Serrano, Beatriz
Papil·lomavirus
Cribratge
Càncer de coll uterí
Papillomaviruses
Medical screening
Cervix cancer
title_short Worldwide use of HPV self-sampling for cervical cancer screening
title_full Worldwide use of HPV self-sampling for cervical cancer screening
title_fullStr Worldwide use of HPV self-sampling for cervical cancer screening
title_full_unstemmed Worldwide use of HPV self-sampling for cervical cancer screening
title_sort Worldwide use of HPV self-sampling for cervical cancer screening
dc.creator.none.fl_str_mv Serrano, Beatriz
Ibáñez, Raquel
Robles, Claudia
Peremiquel Trillas, Paula
Sanjosé Llongueras, Silvia de
Bruni, Laia
author Serrano, Beatriz
author_facet Serrano, Beatriz
Ibáñez, Raquel
Robles, Claudia
Peremiquel Trillas, Paula
Sanjosé Llongueras, Silvia de
Bruni, Laia
author_role author
author2 Ibáñez, Raquel
Robles, Claudia
Peremiquel Trillas, Paula
Sanjosé Llongueras, Silvia de
Bruni, Laia
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Papil·lomavirus
Cribratge
Càncer de coll uterí
Papillomaviruses
Medical screening
Cervix cancer
topic Papil·lomavirus
Cribratge
Càncer de coll uterí
Papillomaviruses
Medical screening
Cervix cancer
description An increasing body of evidence supports the validity of self-sampling as an alternative to clinician collection for primary Human Papillomavirus (HPV) screening. Self-sampling effectively reaches underscreened women and can be a powerful strategy in low- and high-resource settings for all target ages. This work aims to summarize the current use of HPV self-sampling worldwide. It is part of a larger project that describes cervical cancer screening programmes and produces standardized coverage estimates worldwide. A systematic review of the literature and official documents supplemented with a formal World Health Organisation country consultation was conducted. Findings show that the global use of HPV self-sampling is still limited. Only 17 (12%) of countries with identified screening programs recommend its use, nine as the primary collection method, and eight to reach underscreened populations. We identified 10 pilots evaluating the switch to self-sampling in well-established screening programs. The global use of self-sampling is likely to increase in the coming years. COVID-19's pandemic has prompted efforts to accelerate HPV self-sampling introduction globally, and it is now considered a key element in scaling up screening coverage. The information generated by the early experiences can be beneficial for decision-making in both new and existing programs.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/192488
url https://hdl.handle.net/2445/192488
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.ypmed.2021.106900
Preventive Medicine, 2022, vol. 154, p. 106900
https://doi.org/10.1016/j.ypmed.2021.106900
dc.rights.none.fl_str_mv cc by (c) Serrano, Beatriz et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Serrano, Beatriz et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411972208918528
score 15,300719

Similares en LA Referencia